- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune neurological disorder characterized by progressive weakness and sensory dysfunction caused by peripheral nerve damage. It is increasingly recognized due to improved diagnostic tools and growing awareness among healthcare providers and patients
- The escalating demand for effective CIDP treatments is primarily fueled by the rising prevalence of autoimmune and neurological diseases, an aging global population, and expanded access to advanced healthcare services. Innovations in immunotherapy and supportive therapies are further boosting market growth
- North America dominates the chronic inflammatory demyelinating polyneuropathy (CIDP) market with the largest revenue share of 38.9% in 2024, characterized by well-established healthcare infrastructure, increased disease awareness, availability of novel therapies, and a robust presence of leading pharmaceutical companies
- Asia-Pacific is expected to be the fastest growing region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market during the forecast period due to improving healthcare infrastructure, rising patient population, and increasing adoption of advanced treatment modalities in countries such as China, Japan, and India
- Intravenous Immunoglobulin segment dominates the chronic inflammatory demyelinating polyneuropathy (CIDP) market with a market share of 55.5% in 2024, driven by its proven efficacy as the standard first-line therapy, providing symptom relief and improving patient outcomes
